Literature DB >> 24913578

Effect of spiperone on mesenchymal multipotent stromal and hemopoietic stem cells under conditions of pulmonary fibrosis.

E G Skurikhin1, E S Khmelevskaya, N N Ermakova, O V Pershina, A M Reztsova, V A Krupin, I E Stepanova, V M Reztsova, D V Reikhart, A M Dygai.   

Abstract

The antifibrotic properties of spiperone and its effect on stem and progenitor cells were studied on the model of reversible bleomycin-induced pulmonary fibrosis in C57Bl/6 mice. Spiperone reduced infiltration of the alveolar interstitium and alveolar ducts with inflammatory cells and prevented the growth of the connective tissue in the parenchyma of bleomycin lungs. Apart from anti-inflammatory effect, spiperone suppressed bone marrow hemopoietic cells (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119)-, Sca-1+, c-Kit+, CD34- and progenitor hemopoietic cells (granulocyte-erythroid-macrophage-megakaryocytic and granulocyte CFU). Spiperone-induced disturbances of fi brogenesis were paralleled by restoration of endothelial cells in the lung parenchyma, reduction of the number of circulating bone marrow cells and lung mesenchymopoietic cells (mesenchymal multipotent stromal cells (CD31-, CD34-, CD45-, CD44+, CD73+, CD90+, CD106+) and progenitor fi broblast cells), and suppression of multilineage differentiation of multipotent mesenchymal stromal cells (including fi broblast-lineage cells).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24913578     DOI: 10.1007/s10517-014-2508-y

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  1 in total

1.  Micellar Hyaluronidase and Spiperone as a Potential Treatment for Pulmonary Fibrosis.

Authors:  Evgenii Skurikhin; Pavel Madonov; Olga Pershina; Natalia Ermakova; Angelina Pakhomova; Darius Widera; Edgar Pan; Mariia Zhukova; Lubov Sandrikina; Andrey Artamonov; Alexander Dygai
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.